KSGE
Search
- Page Path
- HOME > Search
Original Article
- Value of Fecal Calprotectin Measurement During the Initial Period of Therapeutic Anti-Tubercular Trial
- Hyeong Ho Jo, Eun Young Kim, Jin Tae Jung, Joong Goo Kwon, Eun Soo Kim, Hyun Seok Lee, Yoo Jin Lee, Kyeong Ok Kim, Byung Ik Jang, the Crohn’s and Colitis Association in Daegu-Gyeongbuk
- Clin Endosc 2022;55(2):256-262. Published online November 5, 2021
- DOI: https://doi.org/10.5946/ce.2021.061
-
Abstract
PDF
PubReader
ePub - Background
/Aims: The diagnosis of intestinal tuberculosis (ITB) is often challenging. Therapeutic anti-tubercular trial (TATT) is sometimes used for the diagnosis of ITB. We aimed to evaluate the changing pattern of fecal calprotectin (FC) levels during TATT in patients with ITB.
Methods
A retrospective review was performed on the data of 39 patients who underwent TATT between September 2015 and November 2018 in five university hospitals in Daegu, South Korea. The analysis was performed for 33 patients with serial FC measurement reports.
Results
The mean age of the participants was 48.8 years. The final diagnosis of ITB was confirmed in 30 patients based on complete mucosal healing on follow-up colonoscopy performed after 2 months of TATT. Before starting TATT, the mean FC level of the ITB patients was 170.2 μg/g (range, 11.5-646.5). It dropped to 25.4 μg/g (range, 11.5-75.3) and then 23.3 μg/g (range, 11.5-172.2) after one and two months of TATT, respectively. The difference in mean FC before and one month after TATT was statistically significant (p<0.001), and FC levels decreased to below 100 μg/g in all patients after one month of TATT.
Conclusions
All ITB patients showed FC decline after only 1 month of TATT, and this finding correlated with complete mucosal healing in the follow-up colonoscopy after 2 months of TATT. -
Citations
Citations to this article as recorded by
- Primary Gastric Tuberculosis in an Immunocompetent Patient: The Truth Lying beneath the Surface
Fábio Pereira Correia, Luísa Martins Figueiredo, Luís Carvalho Lourenço, Sofia Santos, Rita Theias Manso, David Horta
GE - Portuguese Journal of Gastroenterology.2024; 31(3): 191. CrossRef - New diagnostic strategies to distinguish Crohn's disease and gastrointestinal tuberculosis
Himanshu Narang, Saurabh Kedia, Vineet Ahuja
Current Opinion in Infectious Diseases.2024; 37(5): 392. CrossRef - Evidence-based approach to diagnosis and management of abdominal tuberculosis
Daya Krishna Jha, Mythili Menon Pathiyil, Vishal Sharma
Indian Journal of Gastroenterology.2023; 42(1): 17. CrossRef - Fecal Calprotectin as a Surrogate Marker for Mucosal Healing After Initiating the Therapeutic Anti-Tubercular Trial
Satimai Aniwan
Clinical Endoscopy.2022; 55(2): 210. CrossRef
- Primary Gastric Tuberculosis in an Immunocompetent Patient: The Truth Lying beneath the Surface
- 4,038 View
- 296 Download
- 4 Web of Science
- 4 Crossref
First
Prev
